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Abstract
Lethal outcomes can be expressed as a case fatality ratio (CFR) or
as a mortality rate per 100 000 population per year (MR).
Population surveillance for community-onset methicillin-sensitive
(MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus
bacteraemia was conducted in Canada, Australia, Sweden and
Denmark to evaluate 30-day CFR and MR trends between 2000
and 2008. The CFR was 20.3% (MSSA 20.2%, MRSA 22.3%) and
MR was 3.4 (MSSA 3.1, MRSA 0.3) per 100 000 per year. Although
MSSA CFR was stable the MSSA MR increased; MRSA CFR
decreased while its MR remained low during the study. Commu-
nity-onset S. aureus bacteraemia, particularly MSSA, is associated
with major disease burden. This study highlights complementary
information provided by evaluating both CFR and MR.
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Death is an important outcome when investigating severe
infections. Case fatality ratio (CFR) expressed as the number
of deaths per cases is typically reported as the primary
indicator of disease severity [1–3]. In comparison, mortality
rate (MR) per 100 000 population per year measures death
events in a population and is less susceptible to selection bias,
thereby potentially being a better marker of disease burden
[4]. Staphylococcus aureus is an important cause of bactera-
emia-associated deaths worldwide. The emergence of meth-
icillin-resistant S. aureus (MRSA) has contributed to its
changing epidemiology. Despite an annual incidence of 25 per
100 000 and a CFR of 15–25%, there are few MR comparisons
[4–9]. In this study, we examined fatal outcomes associated
with community-onset S. aureus bacteraemia. We explored
trends over time and assessed 30-day CFR and MR associated
with MSSA and MRSA.
This study utilized a population-based cohort design. Our
protocol has been previously published [10]. All commu-
nity-onset S. aureus bacteraemias were identiﬁed among
residents of eight regions within Australia (Canberra), Canada
(Calgary, Victoria and Sherbrooke), Denmark (North Den-
mark, Copenhagen City and Copenhagen County) and western
Sweden between 1 January 2000 and 31 December 2008 [5].
Detailed clinical, microbiological and management information
was not available. Thirty-day all-cause death outcome was
available for all centres except Victoria where 30-day in-hos-
pital death was used as a surrogate.
All analyses were conducted using Stata 12.1 (StataCorp,
College Station, TX, USA). Case fatality ratio was calculated as
deaths per cases and expressed as a percentage. The MR was
calculated as deaths per 100 000 population per year and was
age- and gender-standardized to the European Union 27-coun-
try 2007 population [10]. We focused on community-onset
disease and a 30-day time frame to better attribute death to
S. aureus bacteraemia because competing risks (i.e. concurrent
active illnesses) can inﬂuence outcome. The Cuzick non-para-
metric test for trend across ordered groups was used to
compare trends over time.
During the 9-year study period, 5365 incident cases of
community-onset S. aureus bacteraemia were identiﬁed; 5005
(93.3%) MSSA and 360 (6.7%) MRSA. Overall CFR was 20.2%
for MSSA (range, 17.3–22.1% annually) and 22.3% for MRSA
(range, 10.7–47.4% annually), as shown in Figs 1 and 2. The
CFR decreased for MRSA (p 0.05) but remained stable for
MSSA (p 0.81). The overall annual MR was 3.4 (range, 2.7–3.9)
per 100 000, and was 3.1 (range, 2.5–3.7) per 100 000 for
MSSA and 0.3 (range, 0.1–0.4) per 100 000 for MRSA. Annual
MR increased for MSSA (p 0.03) but was similar for MRSA
(p 0.42). Age-adjusted MR was higher for male patients for
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both MSSA (male, 3.6 per 100 000; female, 2.6 per 100 000)
and MRSA (male, 0.3 per 100 000; female, 0.2 per 100 000).
Few population-based studies have reported the CFR or
MR associated with community-onset Staphylococcus aureus
bacteraemia. Studies from the United States (1998), Finland
(1995–2001), Australia (1999–2002) and Canada (2000–2006)
reported incidence rates of 17, 7, 17 and 12 per 100 000 and
associated CFR of 11%, 13%, 18% and 19%, for approximate
overall MR of 2, 1, 3 and 2 per 100 000 per year, respectively
[11–14]. Other population-based studies have either limited
assessment to selected age groups or have not provided data
speciﬁcally for community-onset disease. Our present study is
comparable to these prior studies and overall the body of
available information indicates that community-onset Staphylo-
coccus aureus bacteraemia is associated with an approximate
contemporary incidence of 15 per 100 000 per year, CFR of
20% and MR of 3 per 100 000 per year.
We observed that MSSA MR increased while MSSA CFR
was stable and MRSA CFR decreased while MRSA MR
remained unchanged (Figs 1 and 2). These ﬁndings are largely
related to concurrent changes in incidence. In a popula-
tion-based study, MR can be calculated by multiplying CFR by
disease incidence. We have previously demonstrated increas-
ing incidence of community-onset MSSA and MRSA, particu-
larly among the very young and elderly [5]. As MSSA incidence
has increased yet CFR remained stable, this can be explained
by a proportionate increase in MSSA deaths over the years.
Similarly, rising MRSA incidence but decreasing CFR resulted in
stable MR. In our opinion CFR is a better marker of disease
severity while MR is a better marker of disease burden in a
population. This study highlights important differences in and
complementary information provided by CFR and MR.
Although this study beneﬁts from its large size and interna-
tional scope, there are limitations of note. We did not have
access to co-morbidities, strain characteristics and adequacy of
antibiotic therapy so could not conduct multivariable analysis to
control for confounding effects on outcome [15,16]. Given
concerns about comparison of crude CFR and MR, individual
FIG. 1. Overall 30-day case fatality ratio (CFR) and incidence (IR) and mortality rate (MR) per 100 000 population associated with
methicillin-sensitive Staphylococcus aureus bacteraemia.
FIG. 2. Overall 30-day case fatality ratio (CFR) and incidence (IR) and mortality rate (MR) per 100 000 population associated with
methicillin-resistant Staphylococcus aureus bacteraemia.
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centre results were not approved for individual presentations.
We observed a relatively low overall rate of MRSA infection and
results may not be widely generalizable to populations with
higher rates of disease. It is also important to note that MRSA
case fatality rates demonstrated high variability (range) in the
early years of the study and this was related to small numbers in
the early part of the study (9–13 cases per year during 2000–
2002 vs. 64–82 cases per year during 2006–2008).
In conclusion, this study highlights the different and
complementary information obtained by calculating CFR and
MR in the context of incident rates. While much attention has
been directed to MRSA disease in recent years, MSSA causes a
much greater and increasing burden of disease.
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